Skip to content
Carvedilol
Coreg (carvedilol) is a small molecule pharmaceutical. Carvedilol was first approved as Coreg on 1995-09-14. It is used to treat angina pectoris, heart failure, hypertension, and myocardial infarction in the USA. The pharmaceutical is active against beta-1 adrenergic receptor and beta-2 adrenergic receptor. In addition, it is known to target ryanodine receptor 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Coreg (generic drugs available since 2007-09-05)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carvedilol
Tradename
Company
Number
Date
Products
COREGWoodward Pharma ServicesN-020297 RX1995-09-14
4 products, RLD
Carvedilol phosphate
Tradename
Company
Number
Date
Products
COREG CRWoodward Pharma ServicesN-022012 RX2006-10-20
4 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
carvedilolANDA2023-06-07
coregNew Drug Application2023-04-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
angina pectorisEFO_0003913D000787I20
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
myocardial infarctionEFO_0000612D009203I21
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Carvedilol Phosphate, Coreg Cr, Woodward
81012092025-09-11DP
72681562023-06-27DS, DPU-3, U-313
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AG: Alpha and beta blocking agents
— C07AG02: Carvedilol
— C07F: Beta blocking agents, other combinations
— C07FX: Beta blocking agents, other combinations
— C07FX06: Carvedilol and ivabradine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCARVEDILOL
INNcarvedilol
Description
Carvedilol is a member of the class of carbazoles that is an adrenergic antagonist with non-selective beta- and alpha-1 receptor blocking properties which helps in the management of congestive heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent, an alpha-adrenergic antagonist, a vasodilator agent and a cardiovascular drug. It is a member of carbazoles, a secondary alcohol and a secondary amino compound.
Classification
Small molecule
Drug classvasodilators (undefined group)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
Identifiers
PDB—
CAS-ID72956-09-3
RxCUI—
ChEMBL IDCHEMBL723
ChEBI ID3441
PubChem CID2585
DrugBankDB01136
UNII ID0K47UL67F2 (ChemIDplus, GSRS)
Target
Agency Approved
ADRB1
ADRB1
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB1
Gene synonyms
ADRB1R, B1AR
NCBI Gene ID
153
Protein name
beta-1 adrenergic receptor
Protein synonyms
adrenergic, beta-1-, receptor, Beta-1 adrenoceptor, Beta-1 adrenoreceptor
Uniprot ID
P08588
Mouse ortholog
Adrb1 (11554)
beta-1 adrenergic receptor (P34971)
Alternate
RYR2
RYR2
Organism
Homo sapiens
Gene name
RYR2
Gene synonyms
NCBI Gene ID
6262
Protein name
ryanodine receptor 2
Protein synonyms
Cardiac muscle ryanodine receptor, Cardiac muscle ryanodine receptor-calcium release channel, cardiac-type ryanodine receptor, islet-type ryanodine receptor, kidney-type ryanodine receptor, ryanodine receptor 2 (cardiac), Type 2 ryanodine receptor
Uniprot ID
Q92736
Mouse ortholog
Ryr2 (20191)
ryanodine receptor 2 (Q9ERN6)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 14,206 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16 adverse events reported
View more details